Barclays raised the firm’s price target on Bausch + Lomb (BLCO) to $19 from $18 and keeps an Equal Weight rating on the shares. The firm says ...

InflammX’s pipeline includes an orally dosed therapeutic candidate targeting intermediate age-related macular degeneration ...

Young nearsighted kids who wear bifocal contact lenses that slow uncoordinated eye growth do not lose the benefits of the treatment once they stop wearing the lenses, new research shows.